Enhanced antitumor activity of combination radioimmunotherapy (131I- labeled monoclonal antibody A33) with chemotherapy (Fluorouracil)

Cancer Research

Volumn 57, Issue 11, 1997, Pages 2181-2186

  Tschmelitsch, Jörg ^a   Barendswaard, Els ^a   Williams Jr , Clarence ^a   Yao, Tzy Jyun ^a   Cohen, Alfred M ^a   Old, Lloyd J ^a   Welt, Sydney ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY A33; MONOCLONAL ANTIBODY A33 I 131; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLON CANCER; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LOW ENERGY RADIATION; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; COLON; COLONIC NEOPLASMS; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IODINE RADIOISOTOPES; LEUCOVORIN; MEMBRANE GLYCOPROTEINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0030947492     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Schneebaum, S., and Arnold, M. W. Adjuvant treatment for rectal cancer: current status. Oncology (Basel), 7: 83-90, 1993.
2. Gastrointestinal Tumor Study Group. Prolongation of the disease free interval in surgically treated rectal carcinoma. N. Engl. J. Med., 312: 1465-1472, 1985.
3. Douglass, H. O., Jr., Moertel, C. G., Mayer, R. J., Thomas, P. R., Lindblad, A. S., Mittleman, A., Stablein, D. M., and Bruckner, H. W. Survival after postoperative combination treatment of rectal cancer. N. Engl. J. Med., 315; 1294-1295, 1986.
4. Fisher, B., Wolmark, N., Rockette, H., Redmond, C., Deutsch, M., Wickerham, D. L., Fisher, E. R., Caplan, R., Jones, J., and Lerner, H. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J. Natl. Cancer Inst., 80: 21-28, 1988.
5. Gastrointestinal Tumor Study Group. Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J. Clin. Oncol., 10: 549-557, 1992.
6. Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Bean, U. R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., Twito, D. I., Morton, R. F., Veeder, M. H., Witzig, T. E., Cha, S., and Vidyarthi, S. C. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N. Engl. J. Med., 324: 709-715, 1991.
7. Comis, R. L., and Carter, S. K. Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat. Rev., 1: 221-238, 1974.
8. Ramming, K. P., and Haskell, C. M. Colorectal malignancies. In: C. M. Haskell (ed.), Cancer Treatment, Ed. 2., pp. 295-334. Philadelphia: W. B. Saunders, 1985.
9. Cohen, A. M., Shank, B., and Friedman, M. A. Colorectal cancer. In: V. T. De Vita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer: Principles and Practice of Oncology, Vol. 1, Ed. 3, pp. 895-964. Philadelphia: J. B. Lippincott, 1989.
10. Bleyer, W. A. New vistas for leucovorin in cancer chemotherapy. Cancer (Phila.), 63: 995-1007, 1989.
11. Rustum, Y. M. Toxicity and antitumor activity of 5-fluorouracil in combination with leucovorin. Cancer (Phila.), 63: 1013-1017, 1989.
12. Houghton, J. A., Williams, L. G., Loftin, S. K., Cheshire, P. J., Morton, C. L., Houghton, P. J., Dayan, A., and Jolivet, J. Factors that influence the therapeutic activity of 5-fluorouracil (6RS) leucovorin combinations in colon adenocarcinoma xenografts. Cancer Chemother. Pharmacol., 30: 423-432, 1992.
13. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rates. J. Clin. Oncol., 10: 896-903, 1992.
14. Laufman, L. R., Brenckman, W. D., Stydnicki, K. A., Morgan, E. D., Collier, M., Knick, V. B., Mullin, R., and Ferone, R. Clinical experience with leucovorin and 5-fluorouracil. Cancer (Phila.), 63: 1031-1035, 1989.
15. Arbuck, S. G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of Colorectal cancer. Cancer (Phila.), 63: 1036-1044, 1989.
16. Mini, E., Trave, F., Rustum, Y. M., and Bertino, J. R. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol. Ther., 47: 1-19, 1990.
17. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet, 345: 939-944, 1995.
18. Laufman, L. R., Bukowski, R. M., Collier, M. A., Sullivan, B. A., McKinnis, R. A., Clendennin, N. J., Guaspari, A., and Brenckman, W. D., Jr. A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol., 11; 1888-1893, 1993.
19. Leichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., Meyers, F. J., Holcombe, R. F., Weiss, G. R., and Mangalik, A. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J. Clin. Oncol., 13: 1303-1311, 1995.
20. Fu, K. F., Rayner, P. A., and Lam, K. N. Modification of effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int. J. Radiat. Oncol. Biol. Phys., 10: 1473-1478, 1984.
21. Weinberg, M. J., and Rauth, A. M. 5-Fluorouracil infusions and fractionated doses of radiation: studies with a murine squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 13: 1691-1699, 1987.
22. Byfield, J. E., Chan, P. Y. M., and Seagren, S. L. Radiosensitization by 5-FU: molecular origins and clinical scheduling implications. Proc. Am. Assoc. Cancer Res., 18: 74, 1977.
23. Byfield, J. E., Barone, R. M., Seagren, S. L., Frankel, S., Quinol, L., and Mendelsohn, J. Biweekly infused 5-fluorouracil and X-rays in advanced gastro-intestinal cancer. Proc. Am. Soc. Clin. Oncol., 18: 322-324, 1978.
24. Calabro-Jones, P. M., Byfield, J. E., Ward, J. F., and Sharp, T. R. Time dose relationships for 5-fluorouracil cytotoxicity against human epithelial cells in vitro. Cancer Res., 42: 4413-4415, 1982.
25. Vietti, T., Eggerding, F., and Valeriote, F. Combined effect of X-radiation and 5-fluorouracil on survival of transplanted leukemia cells. J. Natl. Cancer Inst., 47: 865-870, 1971.
26. Welt, S., Divgi, C. R., Kemeny, N., Finn, R. D., Scott, A. M., Graham, M., St. Germain, J., Carswell Richards, E., Larson, S. M., Oettgen, H. F., and Old, L. J. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 12: 1561-1571, 1994.
27. Goldenberg, D. M. (ed.). Cancer Therapy with Radiolabeled Antibodies. Boca Raton: CRC Press, 1995.
28. Welt, S., Divgi, C. R., Real, F. X., Yeh, S. D., Garin Chesa, P., Finstad, C. L., Sakamoto, J., Cohen, A., Sigurdson, E. R., Kemeny, N., Carswell, E. A., Oettgen, H. F., and Old, L. L. Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study with monoclonal antibody A33. J. Clin. Oncol., 8: 1894-1906, 1990.
29. Houghton, P. J., Houghton, J. A., Myers, L., Chesire, P., Howbert, J. J., and Grindey, G. B. Evaluation of N-(5-indanylsulfonyl)-N-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother. Pharmacol., 24: 84-88, 1989.
30. Liang, K., and Zeger, S. L. Longitudinal data analysis using generalized linear models. Biometrika, 73: 13-22, 1986.
31. Riethmüller, G., Schneider-Gädicke, E., Schlimok, G., Schmiegel, W., Raab, R., Höffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayr, R., Buggisch, P., Witte, J., and German Cancer Aid 17-1A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet. 343: 1177-1183, 1994.
32. Gastrointestinal Tumor Study Group. Survival after postoperative combination treatment of rectal cancer. N. Engl. J. Med., 315: 1294-1295, 1986.
33. Bagshaw, M. A. Possible role of potentiators in radiation therapy. Am. J. Roentgenol., 85: 822-833, 1961.
34. Berry, R. J. Effects of some metabolic inhibitors on X-ray dose response curves for the survival of mammalian cells in vitro and on early recovery between fractionated X-ray doses. Br. J. Radiol., 34: 458-465, 1966.
35. Byfield, J. E., Calabro-Jones, P., Klisak, I., and Kulhanian, F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or Ftorafur and X-rays. Int. J. Radiat. Oncol. Biol. Phys., 8: 1923-1933, 1982.
36. Nakajima, V., Miyamoto, Y., Tanabe, M., Watanabe, I., and Terasima, T. Enhancement of mammalian cell killing by 5-fluorouracil in combination with X-rays. Cancer Res., 39: 3763-3767, 1979.
37. Rich, T. A., Kavanaugh, B., Williams, M., Bock, S., Murray, D., Meyn, R., and Brock, W. A. Effects of continuous post-irradiation low dose 5-fluorouracil on log and plateau phase CHO cells. Proceedings, Chemical Modifiers of Cancer Treatment, Clearwater, FL, Abstr. 6-21, 1985.
38. Stephens, J. C., Peacock, S. H., and Steel, G. G. Cell survival in B16 melanoma after treatment with combination of cytotoxic agents: lack of potentiation. Br. J. Cancer, 36: 84-93, 1977.
39. Schein, P. S., Gore, M. E., and Buckman, R. A. Radiation therapy and 5-fluorouracil. Drugs Exp. Clin. Res., 8: 587-592, 1982.
40. Winograd, B., Boven, E., Lobezzo, M. W., and Pinedo, H. M. Human tumor xenografts in the nude mouse and their value as test models in anti-cancer drug development. In Vivo, 1: 1-14, 1987.
41. Schwachofer, J. H. M., Hoogenhout, J., Kal, B., Koedam, J., and Van Wezel, H. P. N. Radiosensitivity of different human tumor lines grown as xenografts determined from growth delay and survival data. In Vivo, 4: 253-258, 1990.
42. Chalandon, Y., Mach, J-P., Pèlegrin, A., Folli, S., and Buchegger, F. Combined radioimmunotherapy and chemotherapy of human colon carcinoma grafted in nude mice: advantages and limitations. Anticancer Res., 12: 1131-1140, 1992.
43. Fowler, J. F. Brief summary of radiobiological principles in fractionated radiotherapy. Semin. Radiat. Oncol., 2: 16-21, 1992.
44. Fowler, J. F. Intercomparisons of new and old schedules in fractionated radiotherapy. Semin. Radial. Oncol., 2: 67-72, 1992.
45. Thames, H. D., Jr, Withers, H. R., and Fletcher, G. H. Changes in early and late radiation responses with altered dose fractionation: implications for dose survival relationship. Int. J. Radiat. Oncol. Biol. Phys., 8: 219-226, 1992.
46. Knox, S. J., Goris, M. L., and Wessels, B. W. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother. Oncol., 23: 111-117, 1992.
47. 131I-labeled monoclonal antibody 17-1A treatment to external beam radiation on the growth of LS174T human colon cancer xenografts. Int. J. Radiat. Oncol. Biol. Phys., 18: 1033-1041, 1990.
48. Buras, R. R., Wong, J. Y. C., and Kuhn, J. A. Comparison of radioimmunotherapy and external beam radiotherapy in colon cancer. Int. J. Radiat. Oncol. Biol. Phys., 16: 12-16, 1991.
49. Knox, S. J., Levy, R., Miller, R. A., Uhland, W., Schiele, J., Ruehl, W., Finston, R., Day-Lollini, P., and Goris, M. L. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res., 50: 4935-4940, 1990.
50. Neacy, W. P., Wessels, B. W., Bradley, E. W., Kovandi, S., Justice, T., Danskin, S., and Sands, H. Comparison of radioimmunotherapy and 4 MV external beam radiotherapy of tumor xenografts in athymic mice. J. Nucl. Med., 27: 902-903, 1986.
51. Palme, D. F., Berkopec, J. M., Elson, M. K., Bono, M. D., Wessels, B. W., Lange, P. H., and Vessella, R. L. Immunotherapy of renal cell carcinoma xenografts by I-131 monoclonal antibody A6H compared to single fraction external beam irradiation. J. Nucl. Med., 28: 651, 1987.
52. Vessella, R. L., Palme, D. F., Berkopec, J. M., Elson, M. K., Truillo, G., Wessels, B. W., and Lange, P. H. A comparison of escalating single and multiple fraction low dose rate radioimmunotherapy with monoclonal antibody A6H I-131 conjugates to high dose rate external beam therapy on human renal cell carcinoma xenografts. J. Nucl. Med., 29: 875, 1988.
53. Wessels, B. W., Vessella, R. L., Palme, D. F., Berkopec, J. M., Smith, G. K., and Bradley, E. W. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int. J. Radial. Oncol. Biol. Phys., 17: 1257-1263, 1989.
54. Welt, S., Scott, A. M., Divgi, C. R., Kemeny, N. E., Finn, R. D., Daghighian, F., St. Germain, J., Richards, E. C., Larson, S. M., and Old, L. J. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J. Clin. Oncol., 14: 1787-1797, 1996.